19 recruiting, 15 unknown, 5 active not recruiting, 5 completed. 55 Phase 1, 21 Phase 2.
Follow B-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of B-cell Acute Lymphoblastic Leukemia trials Research Report on B-cell Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Of KITE-753 in R/R B-Cell ALL KITE-753 - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 18 | 2026-12-31 | 2026-09-11 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-12-01 | 2026-11-09 |
| CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia CD19-Targeted In Vivo CAR-T Injection (first infusion, Day 0); CD22 -Targeted In Vivo CAR-T Injection (second infusion, Day 7) - Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, In Vivo CAR-T | Phase 1 | Recruiting | Liping Dou | 12 | 2026-09-01 | 2026-11-10 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL Antigen-specific T cells CART/CTL and DCvac - B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-11-02 |
| Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells, Fludarabine, Cyclophosphamide - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Ruijin Hospital | 18 | 2026-05-13 | 2026-09-25 |
| Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy - B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 | Recruiting | Beijing GoBroad Hospital | 48 | 2026-03-15 | 2026-03-09 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
| Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 20 | 2026-01-01 | 2026-06-15 |
| Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 30 | 2026-01-01 | 2026-06-25 |
| A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor T Cells (CAR-T) - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | Shanghai Tongji Hospital, Tongji University School of Medicine | 36 | 2025-07-10 | 2025-06-29 |
| A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) HY004, Cyclophosphamide, Fludarabine Phosphate - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Juventas Cell Therapy Ltd. | 2025-06-30 | 2025-08-08 | |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 28 | 2025-05-21 | 2026-02-18 |
| Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies DuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy) - B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | University of Kansas Medical Center | 54 | 2025-03-31 | 2026-05-14 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
| CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL CD19x22 CAR T - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 53 | 2024-09-27 | 2025-11-28 |
| Study of YK012 in B-cell Acute Lymphoblastic Leukemia YK012 - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Excyte Biopharma Ltd | 46 | 2024-09-25 | 2026-02-06 |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) Zilovertamab vedotin - B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 90 | 2024-08-16 | 2026-10-30 |
| Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL CD19-CAR_Lenti_ALLO - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Bambino Gesù Hospital and Research Institute | 24 | 2024-04-28 | 2026-10-20 |
Showing 20 of 55. Sign in to see all of them.
Burkitt Lymphoma (55) · Lymphoma, B-Cell (11) · Recurrence (6) · Lymphoma, Non-Hodgkin (5) · Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Mantle-Cell (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Leukemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Acute (3) · Hematologic Diseases (2) · Leukemia, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma, Follicular (2)
DNA Virus Infections (55) · Epstein-Barr Virus Infections (55) · Hemic and Lymphatic Diseases (55) · Herpesviridae Infections (55) · Immune System Diseases (55) · Immunoproliferative Disorders (55) · Infections (55) · Lymphatic Diseases (55) · Lymphoproliferative Disorders (55) · Neoplasms by Histologic Type (55) · Tumor Virus Infections (55) · Virus Diseases (55) · Neoplasms (54) · Lymphoma (51) · Lymphoma, Non-Hodgkin (50)
Cyclophosphamide (8) · fludarabine (7) · Dexamethasone (4) · Inotuzumab Ozogamicin (4) · blinatumomab (4) · Immunotherapy, Adoptive (3) · Cytarabine (2) · Etoposide (2) · Injections (2) · Prednisone (2) · fludarabine phosphate (2) · tocilizumab (2) · venetoclax (2) · Alemtuzumab (1) · Azacitidine (1)
Liping Dou (3) · Juventas Cell Therapy Ltd. (2) · M.D. Anderson Cancer Center (2) · University of Colorado, Denver (2) · Yan'an Affiliated Hospital of Kunming Medical University (2) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · Anhui Provincial Hospital (1) · Autolus Limited (1) · Bambino Gesù Hospital and Research Institute (1) · BeOne Medicines (1) · Beijing GoBroad Hospital (1) · Belarusian Research Center for Pediatric Oncology, Hematology and Immunology (1) · BioCryst Pharmaceuticals (1) · Bioceltech Therapeutics, Ltd. (1) · British Columbia Cancer Agency (1)
China (23) · United States (20) · Australia (3) · France (3) · United Kingdom (3) · Canada (2) · Italy (2) · South Korea (2) · Taiwan (2) · Belarus (1) · Belgium (1) · Brazil (1) · Chile (1) · Colombia (1) · Czechia (1)
Aibin Liang MD,Ph.D. (1) · Dario Campana (1) · David Shook, MD (1) · Elias Jabbour, MD (1) · Franco Locatelli, MD, PhD (1) · He Huang, PhD (1) · Jae Park, MD (1) · Jeremy Rubinstein, MD, PhD (1) · Jianxiang Wang M.D. (1) · Jie Jin, MD (1) · John Byon, MD, PhD (1) · Joseph McGuirk, D.O. (1) · Kevin Hay, MD (1) · Li Li, MD (1) · Lihua Yang (1)
PMID 28054442, PMID 33308471, PMID 34893603, PMID 36228643, PMID 36821767, PMID 37647601, PMID 40367950, PMID 41671463, PMID 42789493
2016 (2), 2023 (1)